Celcuity Inc. (CELC) FY2024 10-K Annual Report
Celcuity Inc. (CELC) 10-K annual report for fiscal year 2024, filed with SEC EDGAR on Mar 31, 2025. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Celcuity Inc. FY2024 10-K Analysis
Business Overview
- • Core business: Clinical-stage biotech developing gedatolisib, a pan-PI3K/mTOR inhibitor targeting multiple solid tumors, primarily HR+/HER2- advanced breast and metastatic prostate cancer
- • New emphasis: Initiation and enrollment updates for two Phase 3 trials (VIKTORIA-1 completed PIK3CA WT enrollment in Q4 2024; VIKTORIA-2 site activation in Q3 2024, first patient expected Q2 2025)
- • Strategic shift: Focus on combining gedatolisib with CDK4/6 inhibitors to overcome resistance in HR+/HER2- advanced breast cancer after CDK4/6 therapy progression
- • Quantitative highlight: 492 patients treated with gedatolisib to date; Phase 1b trial showed 63% objective response rate in 103 patients with HR+/HER2- advanced breast cancer
- • Noteworthy: FDA Fast Track (Jan 2022) and Breakthrough Therapy Designations (July 2022) granted for gedatolisib, accelerating regulatory path for post-CDK4/6 progression breast cancer
Management Discussion & Analysis
- • No revenue or profitability data disclosed in the provided text
- • No segment performance information available
- • No cash flow, capital allocation, or buyback/dividend details provided
- • Forward-looking statements mentioned with emphasis on risks and uncertainties
- • Reference made to “Risk Factors” section for additional insights
Risk Factors
- • FDA approval risk tied to VIKTORIA-1 trial topline data expected Q2 2025, crucial for gedatolisib market authorization
- • Clinical trial site exposure: 200+ sites across North America, Europe, Latin America, Asia-Pacific for VIKTORIA-1 and VIKTORIA-2 trials
- • Supply risk from dependence on intravenous administration and timely dosing start in Q2 2025 for Phase 3 trial VIKTORIA-2
- • Competitive threat from alpelisib (PIQRAY), an FDA-approved oral PI3K-α inhibitor with 39% grade 3/4 hyperglycemia adverse events
- • Financial risk from $100 million borrowings under Loan Agreement, $10.3 million interest expense in 2024, with loan maturity in May 2029
Celcuity Inc. FY2024 Key Financial MetricsXBRL
Net Income
-$112M
▼ -75.3% YoY
ROE
-96.7%
▼ -5105bp YoY
Total Assets
$245M
▲ +28.2% YoY
EPS (Diluted)
$-2.83
▼ -5.2% YoY
Operating Cash Flow
-$83M
▼ -55.1% YoY
Source: XBRL data from Celcuity Inc. FY2024 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Celcuity Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.